AUMED, a.s. has received permission for a clinical trial, phase III, of the medicinal product TFI

Based on the submitted application and the supplied documents, the State Institute for Drug Control (Czech Republic) has authorized a clinical trial, phase III, of the medicinal product TFI (Transfer Factor) lyophilized mucoadhesive tablet for buccal-oral administration in January 2025. The new medicinal product is based on the results of AUMED’s own research activities in the field of transfer factors. The purpose of this study will be to confirm the efficacy of the medicinal product TFI by demonstrating superiority over placebo. AUMED, a.s. would like to successfully complete the study and proceed with the registration process of the new medicinal product during this year.